Quanterix Corporation reports Q1 2026 results today carrying one of the worst year-to-date performances in its peer group. The stock closed at $3.29 on Wednesday — down 47% for the year — and the setup heading into the print reflects sustained pessimism rather than any sign of a tactical squeeze.
Short sellers remain meaningfully positioned. At roughly 9.1% of the free float, short interest has barely budged. It edged slightly lower over the past week, off about 1.6%, and has been broadly stable for the past month. The borrow market, however, is loose. Availability is generous, and cost-to-borrow has eased to just under 0.5% — a fraction of the 52-week peak in utilization, which hit nearly 57% before collapsing to its current 11.5%. That collapse in utilization over the past six weeks signals that some shorts have already covered, even as the float percentage has stayed elevated. The ORTEX short score sits at 55.8, roughly mid-range — notable but not extreme.
Options positioning adds a mildly cautious tone. The put/call ratio is running at 0.17, about 1.5 standard deviations above its 20-day average of 0.12 — not a defensive extreme, but a step up from the outright bullish tilt the options market held through most of April. The stock bounced 7.9% over the past week yet remains down 13% on the month. That combination — a sharp near-term rally into a deep medium-term hole — points to short covering or positioning ahead of the report rather than any fundamental re-rating.
The analyst view has deteriorated steadily. Canaccord Genuity, the most active firm on the name, halved its price target to $4.00 in April while keeping a Hold rating — the latest move in a downgrade trend that started with a cut from Buy to Hold back in August 2025. The consensus mean target of roughly $5.33 sits well above the current $3.29 print, implying 62% analyst return potential. But that figure deserves caution: the targets aggregated include stale figures from firms that have not rerated since before the stock's multi-year collapse. On the fundamentals, the picture remains challenging. Estimated revenue for the full year runs near $170M with a net loss of roughly $58M and negative operating cash flow around $13M. The price-to-book is close to 1x, suggesting the market is near, but not yet below, book value — a threshold that could attract value-oriented buyers if the company shows any trajectory toward cash-flow stability.
The last earnings release, on March 2, sent the stock down 10% in a single day and 22% over the following five sessions. Today's print therefore tests whether the combination of a near-10% short float and a stock already trading at multi-year lows creates enough of a reset in expectations to break that pattern, or whether another soft quarter deepens the credibility gap between analyst targets and market reality.
See the live data behind this article on ORTEX.
Open QTRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
